Pantoprazole and Colistimethate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Pantoprazole (pantoprazole sodium) and Colistimethate (colistimethate sodium). Common drug interactions include myasthenic syndrome among females and septic shock among males.

The phase IV clinical study analyzes what interactions people have when they take Pantoprazole and Colistimethate. It is created by eHealthMe based on reports of 80 people who take the same drugs from the FDA, and is updated regularly.

What is Pantoprazole?

Pantoprazole has active ingredients of pantoprazole sodium. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 285,165 Pantoprazole users. Check the latest studies of Pantoprazole.

What is Colistimethate?

Colistimethate has active ingredients of colistimethate sodium. eHealthMe is studying from 1,502 Colistimethate users. Check the latest studies of Colistimethate.

On Jul, 13, 2026

80 people who take Pantoprazole and Colistimethate together, and have interactions are studied.

Pantoprazole and Colistimethate drug interactions.

What are the common drug interactions of Pantoprazole and Colistimethate, by gender? *:

female:

Myasthenic syndrome (a group of conditions characterized by muscle weakness (myasthenia) that worsens with physical exertion)
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Cystic fibrosis (disease of the secretary glands)
Dyspnoea (difficult or laboured respiration)
Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system)
Chest discomfort
Hospitalisation
Pruritus generalised (generalized itching)
Confusional state
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)

male:

Septic shock (shock due to blood infection)
Eosinophilia (eosinophil count in the peripheral blood exceeds)
Cerebral ischaemia (insufficient blood flow to the brain to meet metabolic demand)
Cirrhosis alcoholic (chronic disease of the liver marked by degeneration of cells, inflammation, and fibrous thickening of tissue caused by alcoholism)
Cystic fibrosis (disease of the secretary glands)
Electrolyte imbalance
Forced expiratory volume decreased (decreased lung expired air volume)
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Hepatitis (inflammation of the liver)
Hospitalisation

What are the common drug interactions of Pantoprazole and Colistimethate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Dyspnoea (difficult or laboured respiration)
Fatigue (feeling of tiredness)
Hospitalisation

20-29:

Hyperbilirubinaemia (excess of bilirubin in the blood)
Septic shock (shock due to blood infection)
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
Cystic fibrosis (disease of the secretary glands)
Cystic fibrosis lung (fibrosis with cyst in the lung)
Drug ineffective
Dyspnoea (difficult or laboured respiration)
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Pain
Pulmonary function test decreased

30-39:

Cardiac arrest
Cystic fibrosis (disease of the secretary glands)
Hepatitis fulminant (life-threatening condition defined by significantly impaired liver function)
Hospitalisation
Hypotension (abnormally low blood pressure)
Myositis (inflammation of the muscles)
Oedema peripheral (superficial swelling)
Parainfluenzae virus infection
Renal impairment (severely reduced kidney function)
Rib fracture

40-49:

Pruritus generalised (generalized itching)
Chest discomfort
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Muscular weakness (muscle weakness)
Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Antibiotic therapy
Cerebral ischaemia (insufficient blood flow to the brain to meet metabolic demand)
Cough

50-59:

Myasthenic syndrome (a group of conditions characterized by muscle weakness (myasthenia) that worsens with physical exertion)
Cystic fibrosis (disease of the secretary glands)
Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system)
Bronchopulmonary aspergillosis (lung disorder caused by aspergillus fungi)
Hepatitis (inflammation of the liver)
Hypokalaemia (low potassium)
Infusion related reaction
Paralysis flaccid (abnormal condition characterized by the weakening or the loss of muscle tone)
Pneumonia
Pneumonia bacterial (pneumonia associated with bacterial infection)

60+:

Eosinophilia (eosinophil count in the peripheral blood exceeds)
Drug ineffective
Electrolyte imbalance
Flushing (the warm, red condition of human skin)
Hot flush (sudden feelings of heat)
Hypernatraemia (an abnormally high plasma concentration of sodium ions)
Hypertransaminasaemia
Hypoxia (low oxygen in tissues)
Intervertebral disc protrusion (spinal disc protrusion)
Intestinal haemorrhage (bleeding from intestine)

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 36 people, 45.00%
Pneumonia: 7 people, 8.75%
Pain: 6 people, 7.50%
High Blood Pressure: 6 people, 7.50%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 4 people, 5.00%
Klebsiella Infection: 4 people, 5.00%
Cystic Fibrosis Lung (fibrosis with cyst in the lung): 4 people, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Pantoprazole and Colistimethate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously